Genetic

Test Introduced for Analyzing Chromosomal Disorders Before Conception

Published in Gene Therapy Weekly, October 19th, 1998

Vysis, Inc., San Francisco, California, introduced its MultiVysion PB assay, a genetic test that can be used to identify chromosomal abnormalities in polar bodies, genetic material released by the ovum prior to, and immediately following, fertilization.

Now available under the U.S. Food and Drug Administration (FDA)-regulated class, Analyte Specific Reagent (ASR), the MultiVysion PB reagent may help increase the success of in vitro fertilization (IVF) by avoiding the implantation of embryos that contain an abnormal number of a specific chromosome, a condition known as aneuploidy.

The announcement was made at the 54th Annual Meeting of the American...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry